Holen Sie sich die Stockscreener-App
1.11
6.72%
-0.08
Vorhandelsmarkt:
1.13
0.02
+1.80%
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times
Can Pyxis Oncology's CEO Reveal New Cancer Treatment Progress at Upcoming Leerink Conference? - StockTitan
Pyxis Oncology Granted FDA Fast Track Designation for - GlobeNewswire
Pyxis Oncology's US$8.9m Market Cap Fall Books Insider Losses - Simply Wall St
Pyxis Oncology rises on FDA fast track tag for lead asset - MSN
Pyxis Oncology, Inc. Grants Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - Marketscreener.com
FDA fast tracks Pyxis Oncology's head and neck cancer drug By Investing.com - Investing.com Canada
Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer - Nasdaq
PYXSPyxis Oncology, Inc. Latest Stock News & Market Updates - StockTitan
FDA fast tracks Pyxis Oncology’s head and neck cancer drug - Investing.com India
Pyxis Oncology stock up on FDA fast track tag (PYXS:NASDAQ) - Seeking Alpha
Pyxis Oncology Announces Fast Track Designation from FDA for PYX-201 in Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Nasdaq
Could This FDA Fast Track for Pyxis Oncology's Novel Cancer Drug Accelerate Treatment Options? - StockTitan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Pyxis Oncology (NASDAQ:PYXS) Shares Down 4.7% – Here’s What Happened - Defense World
Pyxis Oncology stock hits 52-week low at $1.23 amid downturn By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.23 amid downturn - Investing.com Canada
Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? - Yahoo Finance
Pyxis Oncology Inc [PYXS] Investment Appeal on the Rise - Knox Daily
Nothing is Better Than Pyxis Oncology Inc (PYXS) stock at the moment - SETE News
Pyxis Oncology Inc [PYXS] Investment Guide: What You Need to Know - Knox Daily
Financial Health Report: Pyxis Oncology Inc (PYXS)’s Ratios Tell a Tale - The Dwinnex
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Analysts - Armenian Reporter
Pyxis Oncology Inc (PYXS) Beta Value: Understanding the Market Risk - The News Heater
Pyxis Oncology Inc [PYXS] stock for 174,364 USD was acquired by Connealy Pamela Ann - Knox Daily
A year in review: Pyxis Oncology Inc (PYXS)’s performance in the last year - US Post News
Financial Metrics Unveiled: Pyxis Oncology Inc (PYXS)’s Key Ratios in the Spotlight - The Dwinnex
BlackRock, Inc. Increases Stake in Pyxis Oncology Inc - GuruFocus.com
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Pyxis Oncology Initiates New Combination Trial For PYX-201 And Expands Monotherapy Cohorts - Nasdaq
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial - Marketscreener.com
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of ... - The Bakersfield Californian
Major Clinical Advance: Pyxis Teams with Merck for Groundbreaking Cancer Therapy Trial - StockTitan
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset - MSN
Barclays PLC Purchases 46,997 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Holdings Raised by Jane Street Group LLC - Defense World
Pyxis Oncology stock hits 52-week low at $1.49 By Investing.com - Investing.com South Africa
Pyxis Oncology stock hits 52-week low at $1.49 - Investing.com India
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.43 Average Price Target from Analysts - MarketBeat
Pyxis Oncology, Inc. (NASDAQ:PYXS) Stock Position Raised by Geode Capital Management LLC - Defense World
Barclays PLC Increases Stock Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
State Street Corp Buys 208,344 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pick Pyxis in head and neck despite pullback on ADC phase I? - BioWorld Online
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management - Investing.com Nigeria
Pyxis Oncology stock outlook adjusted with focus on ADC program and cost management By Investing.com - Investing.com South Africa
Pyxis Oncology’s (PYXS) “Outperform” Rating Reiterated at Royal Bank of Canada - Defense World
Pyxis Oncology price target lowered to $8 from $10 at RBC Capital - Yahoo Finance
Pyxis Oncology shares target cut, outperform rating on pipeline update By Investing.com - Investing.com Australia
Pyxis Oncology shares target cut, outperform rating on pipeline update - Investing.com
Pyxis Oncology's (PYXS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move - Benzinga
3.13%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):